JP5373392B2 - 抗ウイルス化合物および方法 - Google Patents

抗ウイルス化合物および方法 Download PDF

Info

Publication number
JP5373392B2
JP5373392B2 JP2008517277A JP2008517277A JP5373392B2 JP 5373392 B2 JP5373392 B2 JP 5373392B2 JP 2008517277 A JP2008517277 A JP 2008517277A JP 2008517277 A JP2008517277 A JP 2008517277A JP 5373392 B2 JP5373392 B2 JP 5373392B2
Authority
JP
Japan
Prior art keywords
guanidine
naphthoyl
virus
pharmaceutical composition
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008517277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543886A (ja
JP2008543886A5 (enExample
Inventor
ゲイリー ディンニーン エワート
ウェイン モリス ベスト
Original Assignee
バイオトロン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005903360A external-priority patent/AU2005903360A0/en
Application filed by バイオトロン リミテッド filed Critical バイオトロン リミテッド
Publication of JP2008543886A publication Critical patent/JP2008543886A/ja
Publication of JP2008543886A5 publication Critical patent/JP2008543886A5/ja
Application granted granted Critical
Publication of JP5373392B2 publication Critical patent/JP5373392B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2008517277A 2005-06-24 2006-06-23 抗ウイルス化合物および方法 Active JP5373392B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2005903360 2005-06-24
AU2005903360A AU2005903360A0 (en) 2005-06-24 Anti-viral compounds and methods
PCT/AU2006/000880 WO2006135978A1 (en) 2005-06-24 2006-06-23 Antiviral compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012209126A Division JP5616410B2 (ja) 2005-06-24 2012-09-24 抗ウイルス化合物および方法

Publications (3)

Publication Number Publication Date
JP2008543886A JP2008543886A (ja) 2008-12-04
JP2008543886A5 JP2008543886A5 (enExample) 2010-09-02
JP5373392B2 true JP5373392B2 (ja) 2013-12-18

Family

ID=37570036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008517277A Active JP5373392B2 (ja) 2005-06-24 2006-06-23 抗ウイルス化合物および方法
JP2012209126A Expired - Fee Related JP5616410B2 (ja) 2005-06-24 2012-09-24 抗ウイルス化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012209126A Expired - Fee Related JP5616410B2 (ja) 2005-06-24 2012-09-24 抗ウイルス化合物および方法

Country Status (16)

Country Link
US (3) US8669280B2 (enExample)
EP (2) EP1902017B1 (enExample)
JP (2) JP5373392B2 (enExample)
KR (2) KR101419327B1 (enExample)
CN (2) CN103274970B (enExample)
AU (1) AU2006261593B2 (enExample)
BR (2) BRPI0612309B8 (enExample)
CA (1) CA2612403C (enExample)
DK (2) DK2826770T3 (enExample)
ES (2) ES2491217T3 (enExample)
NZ (3) NZ596107A (enExample)
PL (2) PL2826770T3 (enExample)
PT (2) PT2826770T (enExample)
SG (1) SG163517A1 (enExample)
WO (1) WO2006135978A1 (enExample)
ZA (1) ZA200800256B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013049676A (ja) * 2005-06-24 2013-03-14 Biotron Ltd 抗ウイルス化合物および方法

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0411900B8 (pt) * 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
EP2148678A4 (en) 2007-05-23 2010-08-04 Siga Technologies Inc ANTIVIRAL DRUGS FOR THE TREATMENT AND PREVENTION OF DENGUE INFECTION
WO2009018609A1 (en) * 2007-08-03 2009-02-12 Biotrom Limited Hepatitis c antiviral compositions and methods
AU2013219202B2 (en) * 2007-08-03 2016-12-08 Biotron Limited Hepatitis C antiviral compositions and methods
JP5569857B2 (ja) * 2007-08-10 2014-08-13 アステラス製薬株式会社 二環式アシルグアニジン誘導体
JPWO2010090305A1 (ja) * 2009-02-09 2012-08-09 アステラス製薬株式会社 置換アシルグアニジン誘導体
EP2394987A4 (en) * 2009-02-09 2012-09-05 Astellas Pharma Inc ACYLGUANIDINDERIVAT
TW201116281A (en) 2009-08-06 2011-05-16 Astellas Pharma Inc N atom containing ring acylguanidine derivatives
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
US9126106B1 (en) 2010-11-05 2015-09-08 Wms Gaming, Inc. Promotional content coordination in wagering game machines
JP5906253B2 (ja) * 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
HRP20220355T1 (hr) 2015-09-16 2022-05-13 Gilead Sciences, Inc. Postupci za liječenje infekcija coronaviridae
AU2018218179B2 (en) * 2017-02-08 2023-05-04 Biotron Limited Methods of treating influenza
CN116036112A (zh) 2017-03-14 2023-05-02 吉利德科学公司 治疗猫冠状病毒感染的方法
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP4512475A3 (en) 2017-07-11 2025-05-14 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
WO2021102508A1 (en) * 2019-11-26 2021-06-03 Biotron Limited Methods of treating hiv-1 infection
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CN118994170A (zh) 2020-03-12 2024-11-22 吉利德科学公司 制备1'-氰基核苷的方法
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
CA3187821A1 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
MX2023002233A (es) 2020-08-24 2023-03-15 Gilead Sciences Inc Compuestos fosfolipidos y usos de estos.
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2022251318A1 (en) 2021-05-26 2022-12-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
AU2022399231A1 (en) * 2021-11-24 2024-05-23 Biotron Limited Methods of treating sars-cov-2 infection
EP4486746A1 (en) 2022-03-02 2025-01-08 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202525810A (zh) 2022-03-02 2025-07-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
CR20240367A (es) 2022-03-03 2024-09-30 Gilead Sciences Inc Compuestos antivirales y métodos de elaboración y uso de los mismos.
WO2023167055A1 (ja) * 2022-03-03 2023-09-07 日本曹達株式会社 抗ウイルス剤
WO2023168254A1 (en) 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CN119604286A (zh) 2022-06-06 2025-03-11 吉利德科学公司 用于治疗包括sars-cov-2的病毒感染的方法
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
WO2024006461A1 (en) 2022-06-30 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
CN115260100B (zh) * 2022-08-08 2023-12-12 赛诺瑞生物医药技术(无锡)有限公司 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
EP4665737A1 (en) 2023-02-16 2025-12-24 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CN121693506A (zh) 2023-08-31 2026-03-17 吉利德科学公司 抗病毒化合物及其制备和使用方法
WO2025054278A1 (en) 2023-09-06 2025-03-13 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734904A (en) * 1956-02-14 Xcxnhxc-nh
US4251545A (en) * 1979-09-19 1981-02-17 Gaf Corporation Fungicidal process using 1-(alkoxyaroyl)guanidines
US4544670A (en) * 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
JPH0218632A (ja) 1988-07-07 1990-01-22 Matsushita Electric Ind Co Ltd 論理ゲート評価装置と論理ゲート評価方法
DE3929582A1 (de) 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4328869A1 (de) 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4421536A1 (de) 1994-06-20 1995-12-21 Hoechst Ag Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JPH08225513A (ja) 1994-12-21 1996-09-03 Kanebo Ltd ナフトイルグアニジン誘導体
DE19518796A1 (de) 1995-05-22 1996-11-28 Hoechst Ag Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19527305A1 (de) 1995-07-26 1997-01-30 Hoechst Ag Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19606355A1 (de) * 1996-02-12 1997-08-14 Schering Ag Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AUPO545297A0 (en) 1997-03-04 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Guanidine derivatives
US20030113352A1 (en) * 2001-12-14 2003-06-19 The Regents Of The University Of California Neutralization of stratum corneum to treat hyperkeratotic skin lesions
WO2004056180A1 (en) * 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery (1)
KR20120045062A (ko) * 2003-03-31 2012-05-08 가부시키가이샤 아루떼꾸 우에노 혈관 과투과 질환의 치료방법
BRPI0411900B8 (pt) 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
US20070099968A1 (en) 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
PT2826770T (pt) * 2005-06-24 2018-12-18 Biotron Ltd Compostos acilguanidinas com atividade antiviral
CN101287702A (zh) * 2005-10-19 2008-10-15 弗·哈夫曼-拉罗切有限公司 N-苯基苯乙酰胺非核苷逆转录酶抑制剂
JP5727842B2 (ja) 2011-04-12 2015-06-03 日野自動車株式会社 車両のインストルメントパネル構造
KR101331921B1 (ko) * 2013-01-16 2013-11-21 에스케이플래닛 주식회사 영유아의 안전을 위한 스마트 인터랙션 서비스를 제공하는 장치 및 방법, 이를 이용한 시스템

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013049676A (ja) * 2005-06-24 2013-03-14 Biotron Ltd 抗ウイルス化合物および方法

Also Published As

Publication number Publication date
CN103274970B (zh) 2015-02-25
CN103274970A (zh) 2013-09-04
JP2008543886A (ja) 2008-12-04
ES2710662T3 (es) 2019-04-26
JP5616410B2 (ja) 2014-10-29
US20090099239A1 (en) 2009-04-16
JP2013049676A (ja) 2013-03-14
PL1902017T3 (pl) 2014-08-29
EP1902017B1 (en) 2014-03-26
CA2612403A1 (en) 2006-12-28
CN101208297B (zh) 2013-04-24
EP1902017A1 (en) 2008-03-26
BR122020006906B8 (pt) 2021-07-27
ZA200800256B (en) 2009-08-26
PT1902017E (pt) 2014-07-11
KR20140072101A (ko) 2014-06-12
US20140066487A1 (en) 2014-03-06
ES2491217T3 (es) 2014-09-05
HK1109615A1 (en) 2008-06-13
EP1902017A4 (en) 2011-12-28
DK1902017T3 (da) 2014-06-30
AU2006261593A1 (en) 2006-12-28
BRPI0612309B1 (pt) 2021-03-02
SG163517A1 (en) 2010-08-30
EP2826770B1 (en) 2018-09-12
EP2826770A1 (en) 2015-01-21
KR101419327B1 (ko) 2014-07-14
US10683263B2 (en) 2020-06-16
NZ610715A (en) 2014-07-25
US20160376231A1 (en) 2016-12-29
HK1206330A1 (en) 2016-01-08
PT2826770T (pt) 2018-12-18
CN101208297A (zh) 2008-06-25
NZ596107A (en) 2013-09-27
CA2612403C (en) 2014-03-25
BR122020006906B1 (pt) 2021-03-16
US8669280B2 (en) 2014-03-11
KR20080021810A (ko) 2008-03-07
BRPI0612309A2 (pt) 2010-11-03
WO2006135978A1 (en) 2006-12-28
US9440926B2 (en) 2016-09-13
NZ564398A (en) 2011-11-25
DK2826770T3 (en) 2019-01-07
BRPI0612309B8 (pt) 2021-05-25
AU2006261593B2 (en) 2013-01-24
PL2826770T3 (pl) 2019-02-28

Similar Documents

Publication Publication Date Title
JP5616410B2 (ja) 抗ウイルス化合物および方法
US20050171196A1 (en) 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
KR102732087B1 (ko) 벤조퓨란계 n-아실하이드라존 유도체를 포함하는 항염증 조성물
US10064843B2 (en) Bis-amide derivative and use thereof
CN113912594A (zh) 硝基噻吩甲胺类光学异构体及其医药用途
HK1206330B (en) Acylguanidine compounds with antiviral activity
AU2013205388B2 (en) Antiviral compounds and methods
CN111559982A (zh) 2-(2-取代-4-羟基嘧啶-5-甲酰胺基)乙酸类化合物及其制备方法与用途
US20090264463A1 (en) Inhibitors Of Protein Phosphatase-1 And Uses Thereof
CN118063386B (zh) (e)-n-[(1h-吲唑-7-基)甲基]-3-芳基丙烯酰胺衍生物的制备及其应用
AU2013219202B2 (en) Hepatitis C antiviral compositions and methods
HK1071752A (en) 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100621

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120627

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130919

R150 Certificate of patent or registration of utility model

Ref document number: 5373392

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250